Cargando…
Phase II study of ramucirumab and docetaxel for previously treated non‐small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study
INTRODUCTION: Anti‐vascular endothelial growth factor therapy has been shown to be effective in non‐small cell lung cancer (NSCLC) patients with malignant pleural effusion (MPE); however, there are no data to suggest that ramucirumab has the same effects. METHODS: We therefore decided to conduct a p...
Autores principales: | Takemoto, Shinnosuke, Fukuda, Minoru, Yamaguchi, Hiroyuki, Ikeda, Takaya, Akagi, Kazumasa, Tomono, Hiromi, Umeyama, Yasuhiro, Dotsu, Yosuke, Taniguchi, Hirokazu, Gyotoku, Hiroshi, Senju, Hiroaki, Kitazaki, Takeshi, Nakatomi, Katsumi, Nagashima, Seiji, Fukuda, Masaaki, Kinoshita, Akitoshi, Soda, Hiroshi, Mukae, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996979/ https://www.ncbi.nlm.nih.gov/pubmed/31851428 http://dx.doi.org/10.1111/1759-7714.13279 |
Ejemplares similares
-
Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study
por: Ikeda, Takaya, et al.
Publicado: (2020) -
Phase II study of IRInotecan treatment after COmbined chemo‐immunotherapy for extensive‐stage small cell lung cancer: Protocol of IRICO study
por: Tomono, Hiromi, et al.
Publicado: (2023) -
Efficacy of S‐1 after pemetrexed in patients with non‐small cell lung cancer: A retrospective multi‐institutional analysis
por: Takemoto, Shinnosuke, et al.
Publicado: (2021) -
Phase II study of nedaplatin and amrubicin as first‐line treatment for advanced squamous cell lung cancer
por: Taniguchi, Hirokazu, et al.
Publicado: (2019) -
Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor
por: Dotsu, Yosuke, et al.
Publicado: (2021)